<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63930">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02127437</url>
  </required_header>
  <id_info>
    <org_study_id>LIPS-01</org_study_id>
    <nct_id>NCT02127437</nct_id>
  </id_info>
  <brief_title>Lanreotide In Polycystic Kidney Disease Study</brief_title>
  <acronym>LIPS</acronym>
  <official_title>Lanreotide In Polycystic Kidney Disease Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IPSEN pharmaceutical company, Boulogne-Billancourt, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <authority>France: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      LIPS study (Lanreotide In Polycystic kidney disease Study) is a prospective randomized
      double blind placebo controlled study. The main objective is to prove that lanreotide, a
      somatostatin analog, is able to reduce the glomerular filtration rate decline over 3 years
      by at least 30%. Cardiovascular outcomes, blood pressure, quality of life and safety are
      among the secondary outcomes. The study, which will include 180 ADPKD patients,  is
      scheduled to start in early 2014.

      An equal number of patients with chronic kidney disease stage 2 (90 patients with GFR 89 to
      60 ml/mn/1.73 m2) and chronic kidney disease stage 3 (90 patients with GFR 59 to 30
      ml/mn/1.73 m2) will be included. The primary endpoint (GFR decline) will be assessed by
      repeated measures, in the overall population as well as in the two GFR stratus.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Glomerular filtration rate (GFR)</measure>
    <time_frame>month 36</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate (GFR)</measure>
    <time_frame>month 18</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate (GFR) decline</measure>
    <time_frame>month 36</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety, tolerance</measure>
    <time_frame>month 36</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset or worsening of hypertension</measure>
    <time_frame>month 18</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset or worsening of hypertension</measure>
    <time_frame>month 36</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>month 0</time_frame>
    <safety_issue>No</safety_issue>
    <description>SF-36, EQ5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>month 18</time_frame>
    <safety_issue>No</safety_issue>
    <description>SF-36, EQ5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>month 36</time_frame>
    <safety_issue>No</safety_issue>
    <description>SF-36, EQ5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cystic pain</measure>
    <time_frame>month 36</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Autosomal Dominant Polycystic Kidney Disease (ADPKD</condition>
  <arm_group>
    <arm_group_label>A - treated group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B - control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanreotide</intervention_name>
    <description>120 mg, subcutaneously, once every 4 weeks</description>
    <arm_group_label>A - treated group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>0,5  ml, subcutaneously, once every 4 weeks</description>
    <arm_group_label>B - control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  autosomal dominant polycystic kidney disease (clinical, familial, imaging grounds)

          -  measured GFR : 30 to 89 ml/mn/1.73m2

          -  age &gt; 18

          -  affiliated with  health insurance

          -  written informed consent

        Exclusion Criteria:

          -  iohexol /iodine allergy

          -  diabetes mellitus

          -  other associated nephropathy suspected

          -  previous malignant disease

          -  cholelithiasis

          -  uncontrolled hypertension (BP&gt;160/100 mmHg)

          -  cardiac failure

          -  liver failure

          -  psychiatric illness

          -  pregnancy, lactation, lack of contraception

          -  use of somatostatin analogs during the last 6 months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique JOLY, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Necker hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominique JOLY, MD PhD</last_name>
    <phone>1 44 49 54 15</phone>
    <phone_ext>+33</phone_ext>
    <email>dominique.joly@nck.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>laurence lecomte, PhD</last_name>
    <phone>1 71 19 64 94</phone>
    <phone_ext>+33</phone_ext>
    <email>laurence.lecomte@nck.aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Necker hospital</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>dominique Joly, MD PhD</last_name>
      <phone>1 44 49 54 15</phone>
      <phone_ext>+33</phone_ext>
      <email>dominique.joly@nck.aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>laurence Lecomte, PhD</last_name>
      <phone>1 71 19 64 94</phone>
      <phone_ext>+33</phone_ext>
      <email>laurence.lecomte@nck.aphp.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>April 28, 2014</lastchanged_date>
  <firstreceived_date>April 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autosomal dominant polycystic kidney disease,</keyword>
  <keyword>Glomerular filtration rate,</keyword>
  <keyword>Somatostatin,</keyword>
  <keyword>lanreotide</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lanreotide</mesh_term>
    <mesh_term>Angiopeptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
